和元生物(688238.SH):在新型CAR-T工藝儲備方面,公司成功搭建mRNA CAR-T電轉工藝平台
格隆匯7月29日丨和元生物(688238.SH)在互動平台表示,CAR-T療法是一種通過基因改造患者自身T細胞,使其能夠精準識別並攻擊癌細胞的創新型細胞免疫療法。在此細分技術領域,公司佈局並在相關技術工藝方面取得了一定成果,其中:①慢病毒載體技術方面,通過優化慢病毒包膜蛋白及NK細胞的轉導等技術,使病毒載體轉導NK細胞的陽性率達到90%,且攻克了生產過程中包裝細胞合胞體形成難題,使慢病毒載體的滴度提升,通過CAR-T相關慢病毒的序列優化,以及使用優選啟動子替換傳統的RSV啟動子,使CAR-T相關慢病毒的產量獲得了進一步的提升;②在新型CAR-T工藝儲備方面,公司成功搭建mRNA CAR-T電轉工藝平台,並完成增強型CAR-T項目工藝突破;並通過戰略合作佈局在in-ViVO CAR-T療法中最先進的mRNA-LNP等非病毒載體的技術儲備;③新型CAR-T技術應用方面,開展了大量平台技術研發,成功建立了T-Flash短時自體CAR-T工藝,並應用於客户IND項目。以上技術儲備直接應用於客户的細胞治療項目中,推動藥物開發進展。截止2025年Q1,公司已協助客户獲得多個國內外IND批件,其產品類型包括CAR-T、Treg、幹細胞等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.